CLAIMS

1.

Sul Sul

A method of treating a B cell malignancy in a subject in need of such treatment comprising administering a therapeutically effective amount of at least one immunoregulating or immunomodulating antibody that is selected from the group consisting of an anti-CD23, anti-B7, anti-CD40, anti-CD40L and anti-CD4 antibody and at least B cell depleting antibody selected from the group consisting of an anti-CD19, anti-CD20, anti-CD22 and anti-CD37 antibody, wherein said antibody administration is effected separately, in combination, and in either order of administration.

口点学学员

2. The method of Claim 1 wherein B cell malignancy is non-Hodgkin's lymphoma.

3. The method of Claim 1 wherein the B cell malignancy is B cell lymphoma.

15

4. The method of Claim 1 wherein the B cell malignancy is a leukemia.

5. The method of Claim 1 wherein treatment comprises the administration of an anti-B7 antibody and an anti-CD20 antibody.

S 2 6.

The method of Claim 5 wherein the anti-CD20 is RITUXAN®.

7. The method of Claim 5 wherein the anti-B7 antibody is a Primatized antibody.

20

8. The method of Claim 7 wherein the anti-B7 induces apoptosis of cancer cells.

- The method of Claim 1 wherein the immunoregulatory antibody is 9. administered after the B cell depleting antibody.
- The method of Claim 1 wherein the immunoregulatory antibody is 10. administered before the B cell depleting antibody.
- 11. The method of Claim 1 wherein the B cell depleting antibody and the immunoregulatory antibody are administered within about a month of each other...
- 12. The method of Claim 1 wherein the B cell depleting antibody and the immunoregulatory antibody are administered within about one week of each other.
- The method of Claim 1 wherein the B cell depleting antibody and the 13. imunoregulatory antibody are administered within about 1 day of each other.
- The method of Claim 1 wherein is used to treat a B cell malignancy 14. selected from the group consisting of relapsed Hodgkin's disease, resistant Hodgkin's disease high grade, low grade and intermediate grade non-Hodgkin's lymphomas, small lymphocytic/B cell chronic lymphocytic leukernia (SLINB-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell/lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL), AIDS- related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic


10

15

20

10

5



15. The method of Claim 14 wherein said B cell malignancy is Hodgkin's disease.

The method of Claim 1 wherein either or both antibody is attached to a radiolobel.

- 17. The method of Claim 1 which further comprises chemotherapy or radiation therapy.
- 18. The method of Claim 1 which includes administration of a non-antibody antagonist specific to CD40L or B7.

55